Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a Multicenter, Non-randomized, Open Label, Multiple Dose, Multiple administration,
Phase IIa Clinical Study Evaluating the Efficacy and Safety of LY01610 in Patients with
Extensive-stage Small Cell Lung Cancer that Progressed after first-line Antitumor Therapy.